Search the Newsreel

Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss

Jasper Therapeutics (JSPR) announced a net loss of $2.8 million for the second quarter ended June 30, 2026. The company recently acquired Kira Pharmaceuticals, raising approximately $132 million, and anticipates releasing interim data and making regulatory filings for its expanded pipeline assets in late …

Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline

(RTTNews) - Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company focused on immune-mediated diseases, reported second quarter 2026 financial results and provided a corporate update following the completion of its acquisition of Kira Pharmaceuticals. The combined company is advancing a portfolio of clinical-stage therapies …

Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary

Jasper Therapeutics, Inc. reported a significant reduction in its net loss for the second quarter of 2026, posting $(2.8M) compared to $(26.7M) in the prior year, with diluted EPS improving to $(0.10) from $(1.74). The company, which remains pre-revenue, highlighted strategic repositioning through the …

Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M

Jasper Therapeutics (JSPR) significantly reduced its net loss in the first half of 2026 to $3.9 million from $48.0 million the previous year, primarily due to lower operating expenses and non-cash adjustments. Subsequent to the quarter, the company acquired Kira Pharmaceuticals, adding new complement-pathway …

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics announced its second quarter 2026 financial results, highlighted by the acquisition of Kira Pharmaceuticals and a successful $132 million PIPE financing. The combined company now possesses a strengthened portfolio of clinical-stage assets for immune-mediated diseases, including KP-104, briquilimab, and KP-701, with sufficient …

JSPR Financials: Income Statement, Balance Sheet & Cash Flow | Jasper Therapeutics Inc

Jash Engineering turns profitable in Q1FY27, revenue up 17%

Piper Sandler Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $2

Piper Sandler has initiated coverage of Jasper Therapeutics (JSPR.US) with a Buy rating. The firm has set a price target of $2 for the company's shares.

Jash Engineering targets ₹1,500 crore revenue by 2030-31

Jash Engineering Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Jash Engineering Q1 Results: Standalone Net Profit Surges to ₹1,338.72 Lakh YoY

Lojas Renner SA (BSP:LREN3) (Q2 2026) Earnings Call Highlights: Record Margins and Digital ...

This article first appeared on GuruFocus. Net Revenue Growth: Retail sales grew 1.1% in Q2 2026, with apparel sales up 2.5%. Two-Year Compound Growth: Retail grew 9.4% on a two-year compound basis, with apparel up 23.1%. Gross Margin (Retail): Record 57.5%, up 0.4 percentage …

Jash Engineering expands foundry capacity, books ₹75 Cr orders in July

Jasper Therapeutics Inc (JSPR) Stock News Today

This article from TradingKey provides a brief update on Jasper Therapeutics Inc (JSPR) stock. It notes the current stock price and highlights that more news will be coming soon regarding earnings, analyst ratings, and key developments. The page serves as a placeholder for future …

Corte no guidance pesa e ações da Lojas Renner tombam mais de 15% após balanço; o que fazer com LREN3 agora?

Jasper Therapeutics (NASDAQ:JSPR): Why Is the Stock Back in Focus as the Latest Update Arrives?

Lojas Quero-Quero (LJQQ3) registra prejuízo de R$ 51,2 mi no 2T26

Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therap

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Jasper Therapeutics, Inc. (NASDAQ:JSPR) securities. The investigation focuses on whether Jasper and its officers engaged in corporate wrongdoing, particularly for investors who purchased shares before November 30, 2023, and continue …

Jason Marine To Go Ex-Dividend On August 6th, 2026 With 0.0075 SGD Dividend Per Share

Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Jasper Therapeutics, Inc. announced that it has received $131.999613 million in funding from a group of investors

Jasper Therapeutics, Inc. announced that it has successfully raised $131.999613 million in funding from a group of 40 investors. The company closed this transaction on August 5, 2026, by issuing 4,656,071 non-voting convertible preferred shares at an issue price of $28.35 per preferred share. …

Jasper Therapeutics (JSPR) completes $131.9M Rule 506(b) private equity sale

Jasper Therapeutics (JSPR) has successfully completed a private exempt equity offering under Rule 506(b) of Regulation D, raising $131,999,611. The offering was fully subscribed with the first sale occurring on July 21, 2026, and no finders' fees were reported. The biotechnology company, incorporated in …

Jasper Therapeutics, Inc. (JSPR) awards 7,500 stock options to director

Jasper Therapeutics, Inc. (JSPR) director Patrick J. Crutcher was granted 7,500 stock options for Voting Common Stock on July 31, 2026. These options, exercisable at $0.63 per share, will vest in full one year from the grant date, subject to his continued service, and …

Permintaan e-KTP & Paspor Naik, Penjualan Jasuindo Tiga (JTPE) Capai Rp 672,9 Miliar

Jasper Therapeutics (JSPR) grants director option for 7,500 shares

Jash Engineering to host Q1FY27 earnings call on Aug 12 at 4:30 PM IST

Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 director, auditor and pay votes

Jasper Therapeutics, Inc. (NASDAQ: JSPR) held its 2026 Annual Meeting of Stockholders on July 31, 2026, where shareholders voted on the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and an advisory vote on …

Tranche Update on Jason Marine Group Limited's Equity Buyback Plan announced on September 1, 2025.

Jasper Therapeutics (JSPR) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for Jasper Therapeutics (JSPR). It includes information about the stock's performance, projected price targets, and a summary of recent analyst actions.

Jasper Therapeutics Company Profile & Introduction

This article provides a company profile and introduction for Jasper Therapeutics. It likely covers key information about the company's operations, mission, and relevant details, serving as a foundational overview for potential investors or interested parties.

Jasper Therapeutics (Nasdaq: JSPR) outlines $30M CVR tied to briquilimab

Jasper Therapeutics (Nasdaq: JSPR) has detailed the terms of its $30 million contingent value right (CVR) associated with its acquisition of Kira Pharmaceuticals. Holders of Jasper's voting common stock immediately prior to the merger are entitled to one contractual CVR per share. This CVR …

Jasper Therapeutics Inc (JSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Jasper Therapeutics Inc (JSPR), detailing its support, resistance, indicators, and moving averages. It includes a breakdown of various technical indicators like MACD, RSI, and KDJ, alongside moving average signals. The analysis aims to offer investors reference points …

Jasper Therapeutics, Inc. Revenue Breakdown – BOATS:JSPRW

This article provides details for Jasper Therapeutics, Inc. (JSPRW) on the TradingView platform. It highlights that the stock symbol refers to the Blue Ocean Alternative Trade System (BOATS). The content primarily points to different financial data, documents, news, and community features available for JSPRW …